Next Article in Journal
A Radiogenomic Approach for Decoding Molecular Mechanisms Underlying Tumor Progression in Prostate Cancer
Next Article in Special Issue
Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression
Previous Article in Journal
Cancers after Chornobyl: From Epidemiology to Molecular Quantification
Previous Article in Special Issue
Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells
Review

Cutaneous Metastases in Ovarian Cancer

Department of Obstetrics and Gynecology, Kameda Medical Center, Kamogawa 296-8602, Chiba, Japan
Cancers 2019, 11(9), 1292; https://doi.org/10.3390/cancers11091292
Received: 20 June 2019 / Revised: 20 August 2019 / Accepted: 28 August 2019 / Published: 2 September 2019
(This article belongs to the Special Issue Ovarian Cancer Metastasis)
Skin metastases in ovarian cancer are uncommon, but their incidence may be increasing due to improved survival rates. Skin metastases can be divided into umbilical metastases, which are known as Sister Joseph nodules (SJNs) and are associated with peritoneal metastasis, and non-SJN skin metastases, which usually develop within surgical scars and in the vicinity of superficial lymphadenopathy. As most skin metastases develop after specific conditions, recognition of preceding metastatic diseases and prior treatments is necessary for early diagnosis of skin lesions. The prognosis of skin metastases in ovarian cancer varies widely since they are heterogeneous in the site of lesion and the time of appearance. Patients with SJNs at initial diagnosis and patients with surgical scar recurrences without concomitant metastases may have prolonged survival with a combination of surgery and chemotherapy. In patients who developed skin recurrences as a late manifestation, symptoms should be treated with external beam radiotherapy and immune response modifiers. Immune checkpoint blockade can enhance anti-tumor immunity and induce durable clinical responses in multiple tumor types, including advanced chemoresistant ovarian cancer. With the use of radiation therapy, which enhances the systemic anti-tumor immune response, immune checkpoint blockade may be a promising therapeutic strategy for distant metastasis, including skin metastasis. View Full-Text
Keywords: ovarian cancer; skin metastasis; radiation therapy; immune checkpoint blockade ovarian cancer; skin metastasis; radiation therapy; immune checkpoint blockade
Show Figures

Figure 1

MDPI and ACS Style

Otsuka, I. Cutaneous Metastases in Ovarian Cancer. Cancers 2019, 11, 1292. https://doi.org/10.3390/cancers11091292

AMA Style

Otsuka I. Cutaneous Metastases in Ovarian Cancer. Cancers. 2019; 11(9):1292. https://doi.org/10.3390/cancers11091292

Chicago/Turabian Style

Otsuka, Isao. 2019. "Cutaneous Metastases in Ovarian Cancer" Cancers 11, no. 9: 1292. https://doi.org/10.3390/cancers11091292

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop